News

GSK reports long-term benefit of Nucala

Country
United Kingdom

A multi-year study of the asthma drug Nucala (mepolizumab) has shown the treatment to be effective in asthma control and reducing acute episodes of the disease, according to GlaxoSmithKline Plc. The company disclosed the data on 20 May at a meeting of the American Thoracic Society.

Positive Phase 3 results for Dupixent

Country
France

Dupixent (dupilumab) has delivered positive results in a Phase 3 trial involving adolescents with moderate-to-severe atopic dermatitis. The drug is already approved for the same disease in adults and is the first biologic to show a benefit in this patient group.

NOXXON gives update on cancer study

Country
Germany

NOXXON Pharma NV has reported a promising response from a patient with metastatic pancreatic cancer to its RNA oligonucleotide drug that is intended to fight cancer by targeting the tumour microenvironment. The company gave the update on 16 May at the BioEquity Europe conference in Belgium.

AZ and Emulate in drug safety alliance

Country
United Kingdom

AstraZeneca Plc is to use organ-on-chip technology to test drug compounds for safety and efficacy under a new collaboration with the Boston, Massachusetts, US company Emulate Inc. Emulate will co-locate scientists within AstraZeneca’s laboratories in the UK where the chips will be tested across the AZ pipeline.

AZ sees return to growth

Country
United Kingdom

AstraZeneca Plc expects to return to growth in 2018 as new oncology, diabetes and cardiovascular products boost group sales, offsetting the loss of market share for the statin Crestor which faces generic competition in Europe and Japan.

AZ drug for COPD fails first of two Phase 3 trials

Country
United Kingdom

AstraZeneca Plc’s antibody drug for chronic obstructive pulmonary disease (COPD), Fasenra (benralizumab), has failed to meet its primary endpoint in the first of two Phase 3 trials of patients with the disease.

Growth for Lundbeck depression drugs

Country
Denmark

H. Lundbeck A/S recorded double-digit growth for its portfolio of new drugs for depression and schizophrenia in the first quarter, offsetting the loss of sales arising from generic competition. Group revenue for the quarter was DKK 4.6 billion (€615.4 million), up by 9% from a year earlier.

Genmab more than doubles Q1 sales

Country
Denmark

An unusual combination of events drove revenue at Genmab A/S up by DKK 430 million to DKK 681 million (€91.4 million) in the first quarter, for an increase of 171% compared with a year earlier. Operating income consequently rose to DKK 324 million from DKK 46 million the previous year.

FDA seeks action against stem cell clinics

Country
United States

The US Food and Drug Administration has requested permanent injunctions against stem cell clinics in two regions of the country to prevent them from administering unapproved stem cell treatments to patients with cancer and other diseases. The move comes nearly 10 months after it issued warning letters to the clinics.

Roche combination trial fails

Country
Switzerland

A Phase 3 trial evaluating a combination of the checkpoint antibody Tecentriq (atezolizumab) and the kinase inhibitor Cotellic (cobimetinib) in patients with metastatic colorectal cancer failed to meet its primary endpoint of overall survival, Roche announced on 10 May.